The Tribunal made an order on 3 August 2021 granting an extension of time for Advanz Pharma Corp to file a notice of appeal in respect of the CMA's Liothyronine Decision due to exceptional circumstances.
By Order of the Chairman dated 5 October 2021, the time for the CMA to file a single Defence in the Hydrocortisone appeals was extended to 1 December 2021.
Summary of appeal published on 27 October 2021.
A case management conference took place on 8 December 2021, at which the Tribunal made case management directions and ordered that all appeals of the CMA's Hydrocortisone Decision will be case managed together (the "Hydrocortisone Proceedings").
A second case management conference took place remotely on 21 January 2022, following which the Tribunal made directions for the Hydrocortisone Proceedings to be progressed and case managed through the use of Ambulatory Drafts.
A third case management conference has been scheduled for 25 July 2022, with a time estimate of one day.
The hearing of the Hydrocortisone Proceedings has been listed for the week commencing 21 November 2022 with a time estimate of 3 weeks, with 2 weeks held in reserve.